Table 3.
Baseline characteristics of 247 patients with E. coli bacteremia who received CPZ/SUL treatment
| Variables | n/Na | |
|---|---|---|
| Demographics | ||
| Age, year ± SD | 73.0 | ± 13.6 |
| Male, sex | 124 | (50.2) |
| Comorbidities | ||
| Heart failure | 22 | (8.9) |
| Hypertension | 152 | (61.5) |
| Diabetes mellitus | 101 | (40.9) |
| Chronic liver diseases | 40 | (16.2) |
| Chronic kidney diseases | 33 | (13.4) |
| Peptic ulcer | 29 | (11.7) |
| Malignancy | 60 | (24.3) |
| CCI ≥ 3 | 108 | (43.7) |
| Clinical severity | ||
| SOFA score, mean ± SD | 2.52 | ± 2.48 |
| Shock | 21 | (8.5) |
| Pitt bacteremia score ≥ 4 | 11 | (4.5) |
| Source of bacteremia | ||
| Primary bacteremia | 59 | (23.9) |
| Intra-abdominal | 39 | (15.8) |
| Urinary tract | 114 | (46.2) |
| Low respiratory tract | 12 | (4.9) |
| CRBSI | 3 | (1.2) |
| Soft tissue infection | 4 | (1.6) |
| Others | 16 | (6.5) |
| CPZ/SUL therapy | ||
| Daily dosage | ||
| 2 g/2 g | 189 | (76.5) |
| 1 g/1 g | 50 | (20.2) |
| 0.5 g/0.5 g | 8 | (3.2) |
| Duration, days ± SD | 7.9 | ± 3.5 |
CPZ/SUL cefoperazone/sulbactam, CCI Charlson comorbidity index, CRBSI catheter-related bloodstream infection, SOFA sequential organ failure assessment
aValues are reported as no./total no. (%) of patients or episodes unless otherwise indicated